The OrthoPure XT decellularised xenograft ligament utilises Leeds-based Tissue Regenix's patented dCell technology

OrthoPure XT was commercially launched in December 2020 after being awarded a CE Mark for revision of anterior cruciate ligament (ACL) reconstruction procedures and reconstruction of other knee ligaments, including multiligament and primary procedures when the autograft is unacceptable.

The biocompatible implant provides a biomechanically appropriate tissue scaffold for cellular repopulation and eventual regeneration.

The multiyear distribution agreement covers Italy currently but also has the potential for extension to wider geographies.

As part of the agreement, Geistlich has also committed to advance the clinical science surrounding OrthoPure XT which will be conducted at some of the leading institutions by clinicians in Italy.

Filippo Baldini, national sales manager for Geistlich Biomaterials Italia, said: "Geistlich is excited to bring this new technology to the Italian market and serve the patient's needs with this innovative solution."

Professor Stefano Zaffagnini, of the Istituto Ortopedico Rizzoli in Bologna, Italy, said: "Our centre has demonstrated an interest in xenograft options for our patients and the OrthoPure XT has the potential to address needs in knee surgeries."

Daniel Lee, CEO of Tissue Regenix, said: "We are pleased to partner with Geistlich for our commercial efforts in Italy. Geistlich is a leader in regenerative products, so our commitments are aligned in delivering innovative products to advance patient care.

"We are excited to work with them to build the clinical experience with OrthoPure XT and introduce this transformative product to the Italian medical community."

---

Support The Yorkshire Post and become a subscriber today.

Your subscription will help us to continue to bring quality news to the people of Yorkshire. In return, you'll see fewer ads on site, get free access to our app and receive exclusive members-only offers.

So, please - if you can - pay for our work. Just £5 per month is the starting point. If you think that which we are trying to achieve is worth more, you can pay us what you think we are worth. By doing so, you will be investing in something that is becoming increasingly rare. Independent journalism that cares less about right and left and more about right and wrong. Journalism you can trust.

Thank you

James Mitchinson

Leeds-based TissueRegenix signs distribution agreement with Italian firm Geistlich